CBP/p300-IN-22
CBP/p300-IN-22 is a selective CBP/EP300-BRD inhibitor with an IC50 of 4 nM. CBP/p300-IN-22 is highly selective over BRD4 (1) . CBP/p300-IN-22 reduces TNF-α-induced cytokine expression and subsequent immune cell recruitment by inhibiting NF-κB signaling, and has anticancer activity. CBP/p300-IN-22 can be used for the research of rheumatoid arthritis (RA) and other TNF-α-mediated inflammatory conditions[1].
Product Specifications
UNSPSC
12352005
Target
Epigenetic Reader Domain; Histone Acetyltransferase; NF-κB
Related Pathways
Epigenetics; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Smiles
CC1=CC2=C(NC(C3=CC(C4=NN(C)C=C4)=CC(NC(C5=CC=CO5)=O)=C3)=O)C=CC=C2N=N1
Molecular Formula
C25H20N6O3
Molecular Weight
452.46
References & Citations
[1]Gosselé KA, et al. Selective CBP/EP300 Bromodomain Inhibitors: Novel Epigenetic Tools to Counter TNF-α-Driven Inflammation. JACS Au. 2025 Jun 5;5 (6) :2491-2499.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD4; CBP/p300
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740040-100 1x 100 µL
CD35 / CR1 (E11), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880050-500 1x 500 µL
IgA Secretory Component (SC05), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680679-100 1x 100 µL
CD171 / L1CAM (L1 Cell Adhesion Molecule) (UJ127), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC681951-500 1x 500 µL
Bcl-6 (Follicular Lymphoma Marker) (BCL6/1951R), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC472579-500 1x 500 µL
CD10 (Membrane Metalloendopeptidase) (MME/2579), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC941992-500 1x 500 µL
Cytokeratin 20 (KRT20) (Colorectal Epithelial Marker) (KRT20/1992), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details